HealthEquity, Inc. (NASDAQ:HQY) Director Frank Medici sold 316,644 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $51.96, for a total transaction of $16,452,822.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Frank Medici also recently made the following trade(s):

  • On Thursday, July 13th, Frank Medici sold 131,800 shares of HealthEquity stock. The shares were sold at an average price of $51.42, for a total transaction of $6,777,156.00.
  • On Wednesday, July 12th, Frank Medici sold 332,511 shares of HealthEquity stock. The shares were sold at an average price of $51.13, for a total transaction of $17,001,287.43.
  • On Friday, July 14th, Frank Medici sold 537,102 shares of HealthEquity stock. The shares were sold at an average price of $51.24, for a total transaction of $27,521,106.48.

HealthEquity, Inc. (NASDAQ HQY) traded down 0.02% during trading on Tuesday, hitting $51.34. 323,384 shares of the stock traded hands. The stock has a market cap of $3.11 billion, a PE ratio of 76.17 and a beta of 1.80. The company has a 50-day moving average price of $46.41 and a 200 day moving average price of $46.70. HealthEquity, Inc. has a one year low of $30.34 and a one year high of $54.95.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Tuesday, September 5th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.13. HealthEquity had a return on equity of 13.93% and a net margin of 20.27%. The firm had revenue of $56.90 million during the quarter, compared to analyst estimates of $55.66 million. During the same period in the prior year, the company posted $0.16 earnings per share. The business’s revenue for the quarter was up 28.7% compared to the same quarter last year. Analysts expect that HealthEquity, Inc. will post $0.71 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “HealthEquity, Inc. (HQY) Director Frank Medici Sells 316,644 Shares” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/10/healthequity-inc-hqy-director-frank-medici-sells-316644-shares.html.

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in HealthEquity by 6.2% during the first quarter. Vanguard Group Inc. now owns 4,115,237 shares of the company’s stock worth $174,691,000 after acquiring an additional 240,136 shares in the last quarter. Paloma Partners Management Co acquired a new position in HealthEquity during the first quarter worth $503,000. First Trust Advisors LP raised its stake in HealthEquity by 17.0% during the second quarter. First Trust Advisors LP now owns 94,283 shares of the company’s stock worth $4,698,000 after acquiring an additional 13,676 shares in the last quarter. Royce & Associates LP raised its stake in HealthEquity by 18.0% during the second quarter. Royce & Associates LP now owns 139,200 shares of the company’s stock worth $6,936,000 after acquiring an additional 21,200 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in HealthEquity during the second quarter worth $1,362,000. Hedge funds and other institutional investors own 90.97% of the company’s stock.

Several analysts have weighed in on the stock. BidaskClub upgraded shares of HealthEquity from a “sell” rating to a “hold” rating in a research note on Thursday, September 28th. Cantor Fitzgerald reiterated a “buy” rating and set a $56.00 target price on shares of HealthEquity in a research note on Monday, September 25th. Robert W. Baird reiterated a “hold” rating on shares of HealthEquity in a research note on Thursday, September 21st. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $61.00 target price on shares of HealthEquity in a research note on Wednesday, September 6th. Finally, Zacks Investment Research lowered shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. HealthEquity currently has an average rating of “Buy” and a consensus target price of $56.50.

About HealthEquity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.